ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Functional inhibition of the RNA‐binding protein HuR sensitizes triple‐negative breast cancer to chemotherapy
dc.contributor.author | Wei, Lanjing | |
dc.contributor.author | Zhang, Qi | |
dc.contributor.author | Zhong, Cuncong | |
dc.contributor.author | He, Lily | |
dc.contributor.author | Zhang, Yuxia | |
dc.contributor.author | M. Armaly, Ahlam | |
dc.contributor.author | Aubé, Jeffrey | |
dc.contributor.author | R. Welch, Danny | |
dc.contributor.author | Xu, Liang | |
dc.contributor.author | Wu, Xiaoqing | |
dc.date.accessioned | 2024-06-04T15:27:49Z | |
dc.date.available | 2024-06-04T15:27:49Z | |
dc.date.issued | 2023-07-19 | |
dc.identifier.citation | Wei L, Zhang Q, Zhong C, He L, Zhang Y, Armaly AM, Aubé J, Welch DR, Xu L, Wu X. Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy. Mol Oncol. 2023 Oct;17(10):1962-1980. doi: 10.1002/1878-0261.13478. Epub 2023 Jul 19. PMID: 37357618; PMCID: PMC10552894 | en_US |
dc.identifier.uri | https://hdl.handle.net/1808/35097 | |
dc.description.abstract | Chemotherapy remains the standard treatment for triple‐negative breast cancer (TNBC); however, chemoresistance compromises its efficacy. The RNA‐binding protein Hu antigen R (HuR) could be a potential therapeutic target to enhance the chemotherapy efficacy. HuR is known to mainly stabilize its target mRNAs, and/or promote the translation of encoded proteins, which are implicated in multiple cancer hallmarks, including chemoresistance. In this study, a docetaxel‐resistant cell subline (231‐TR) was established from the human TNBC cell line MDA‐MB‐231. Both the parental and resistant cell lines exhibited similar sensitivity to the small molecule functional inhibitor of HuR, KH‐3. Docetaxel and KH‐3 combination therapy synergistically inhibited cell proliferation in TNBC cells and tumor growth in three animal models. KH‐3 downregulated the expression levels of HuR targets (e.g., β‐Catenin and BCL2) in a time‐ and dose‐dependent manner. Moreover, KH‐3 restored docetaxel's effects on activating Caspase‐3 and cleaving PARP in 231‐TR cells, induced apoptotic cell death, and caused S‐phase cell cycle arrest. Together, our findings suggest that HuR is a critical mediator of docetaxel resistance and provide a rationale for combining HuR inhibitors and chemotherapeutic agents to enhance chemotherapy efficacy. | en_US |
dc.publisher | FEBS PRESS | en_US |
dc.rights | Copyright © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Animal tumor model | en_US |
dc.subject | Chemoresistance | en_US |
dc.subject | Docetaxel | en_US |
dc.subject | HuR | en_US |
dc.subject | TNBC | en_US |
dc.title | Functional inhibition of the RNA‐binding protein HuR sensitizes triple‐negative breast cancer to chemotherapy | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Zhang, Qi | |
kusw.kudepartment | Department of Molecular Biosciences | en_US |
dc.identifier.doi | 10.1002/1878-0261.13478 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-9170-0931 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-9196-4232 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-2076-4107 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC10552894 | en_US |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: Copyright © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.